Extended duration of letermovir prophylaxis: how long is long enough?

Douglas, Abby P; Slavin, Monica A

Douglas, Abby P; Slavin, Monica A.

Afiliação

Douglas AP; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Department of Infectious Diseases, Austin Health, Heidelberg, VIC, Australia. Electronic address: abby.douglas@petermac.org.
Slavin MA; National Centre for Infections in Cancer, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Department of Infectious Diseases, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Department of Health Services Research and Implementation Science, Peter MacCallum Cancer Centre, Melbourne, VIC 3000, Australia; Sir Peter MacCallum Department of Oncology, University of Melbourne, Melbourne, VIC, Australia; Department of Infectious Diseases, University of Melbourne, Melbourne,

Lancet Haematol ; 11(2): e88-e90, 2024 02.

Article em En | MEDLINE | ID: mdl-38142694

Assuntos

Antivirais; Transplante de Células-Tronco Hematopoéticas; Humanos; Antivirais/uso terapêutico; Acetatos; Quinazolinas

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Antivirais / Transplante de Células-Tronco Hematopoéticas Idioma: En Ano de publicação: 2024 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google